Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas.
Grounded in the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, we’re developing products at the intersection of biomaterials and pharmaceuticals.
We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development while making a difference in patient outcomes.
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more
AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation. Watch the animated explainer inside this article.Read more